

# FULVESTRANT

BRAND NAME	FASLODEX, FULVESTRANT ACCORD, EVER PHARMA, SANDOZ
DRUG CLASS	Anti-estrogen
AVAILABILITY	Prefilled syringe contains 250 mg/5 mL of fulvestrant. Also contains ethanol 96%, benzyl alcohol, benzyl benzoate and castor oil. <sup>1</sup> The solution is viscous, clear and colourless to yellow. <sup>1</sup>
pH	No information
PREPARATION	Ready to use. Allow the syringe to reach room temperature before use. <sup>2</sup>
STABILITY	<b>Faslodex, Accord</b> and <b>Sandoz</b> : store at 2 to 8 °C. Protect from light. <sup>1</sup> <b>Faslodex</b> is stable for a cumulative total of 28 days below 25 °C. <sup>3</sup> <b>Ever Pharma</b> : store below 25 °C. Protect from light. <sup>1</sup>
ADMINISTRATION	
<b>IM injection</b>	Inject slowly into the gluteal muscle over 1 to 2 minutes. <sup>1</sup> The ventrogluteal site is preferred.
<b>SUBCUT injection</b>	Not recommended
<b>IV injection</b>	Contraindicated
<b>IV infusion</b>	Contraindicated
COMPATIBILITY	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	May cause hypersensitivity reactions including angioedema and urticaria. <sup>1</sup> May cause injection site reactions and pain. <sup>1</sup>

## REFERENCES

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 30/03/2022.
2. Fulvestrant. In: Clinical drug information [internet]. Bethesda, MD: American Society of Health-System Pharmacists; 2019. Accessed 08/02/2019.
3. Faslodex. Summary of product characteristics. Macclesfield, UK: AstraZeneca UK. Approved 10/03/2004. Updated 01/01/2021. Available from [www.medicines.org.uk](http://www.medicines.org.uk). Accessed 30/03/2021.